Reversed-phase high-performance liquid chromatography method for simultaneous analysis of two liposome-formulated short interfering RNA duplexes

Analytical Biochemistry

Volumn 401, Issue 1, 2010, Pages 61-67

  Murugaiah, Veeravagu ^a   Zedalis, William ^a   Lavine, Gary ^a   Charisse, Klaus ^a   Manoharan, Muthiah ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Cationic liposome; Ion pair reversed phase HPLC; Oligonucleotide; SiRNA; Stability

Indexed keywords

COMPLEXATION; CONVERGENCE OF NUMERICAL METHODS; DRUG DELIVERY; DRUG PRODUCTS; IONS; LIPOSOMES; LIQUIDS; MASS SPECTROMETRY; METHANOL; OLIGONUCLEOTIDES; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; PROPANOL; RNA;

CATIONIC LIPOSOMES; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; RELATIVE STANDARD DEVIATIONS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVERSED PHASE HPLC; SHORT INTERFERING RNA (SIRNA); SIRNA; THERAPEUTIC APPLICATION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

HEXAFLUORO 2 PROPANOL; LIPOSOME; METHANOL; SMALL INTERFERING RNA; TRIETHYLAMINE;

ACCURACY; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG IMPURITY; DRUG STABILITY; ENCAPSULATION; GENE SILENCING; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY;

EID: 77951091588     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.02.012     Document Type: Article

References (43)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15:188-200.
3. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
4. Jorgensen R. Altered gene expression in plants due to trans interactions between homologous genes. Trends Biotechnol. 1990, 8:340-344.
5. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101:22-33.
6. Bass B.L. Double-stranded RNA as a template for gene silencing. Cell 2000, 101:235-239.
7. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W.Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2:711-719.
8. Grimm D., Kay M.A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. J. Clin. Invest. 2007, 117:3633-3641.
9. De Fougerolles A., Vornlocher H., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
10. Durcan N., Murphy C., Cryan S. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol. Pharm. 2008, 5:559-566.
11. Nguyen1 T., Menocal1 E.M., Harborth J., Fruehauf J.H. RNAi therapeutics: an update on delivery. Curr. Opin. Mol. Ther. 2008, 10:158-167.
12. Beaucage S.L., Iyer R.P. The functionalization of oligonucleotides via phosphoramidite derivatives. Tetrahedron 1993, 49:1925-1963.
13. Sproat B.S. RNA synthesis using 2′-O-(tert-butyldimethylsilyl) protection. Methods in Molecular Biology 2005, vol. 288:17-31. Humana Press, Totowa, NJ.
14. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 2004, 8:570-579.
15. Corey D.R. Chemical modification: the key to the clinical application of RNA interference?. J. Clin. Invest. 2007, 117:3615-3622.
16. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117:3623-3632.
17. Lappalainen K., Miettinen R., Kellokoski J., Jaaskelainen I., Syrjanen S. Intracellular distribution of oligonucleotides delivered by cationic liposomes: light electron microscopic study. J. Histochem. Cytochem. 1997, 45:265-274.
18. Fenske D.B., Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 2005, 391:7-40.
19. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
20. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 2005, 107:276-287.
21. Torcilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
22. Maurer N., Wong K.F., Stark H., Louie L., McIntosh D., Wong T., Scherrer P., Semple S., Cullis P.R. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 2001, 80:2310-2326.
23. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., Jayaprakash K.N., Jayaraman M., Rajeev K., Manoharan M., Koteliansky V., Röhl I., Leshchiner E.S., Langer R., Anderson D.G. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 2009, 17:872-879.
24. Food and Drug Administration, Guidance for Industry on Liposome Drug Products, FDA, 2002, pp. 1-15.
25. Furneri P.M., Fresta M., Puglisi G., Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob. Agents Chemother. 2000, 44:2458-2464.
26. Ho J.A., Wu L., Huang M.R., Lin Y.J., Baeumner A.J., Durst R.A. Application of ganglioside-sensitized liposomes in a flow injection immunoanalytical system for the determination of cholera toxin. Anal. Chem. 2007, 79:246-250.
27. 2+-drug complexes. Biochim. Biophys. Acta 1998, 1414:205-216.
28. Chen D., Cole D.L., Srivatsa G.S. Determination of free and encapsulated oligonucleotides in liposome formulated drug product. J. Pharm. Biomed. Anal. 2000, 22:791-801.
29. Wang S., Shi Z., Liu W., Jules J., Feng X. Development, validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing. BMC Biotechnol. 2006, 6:50.
30. Pfister E.L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., Landwehrmeyer B., Vonsattel J.P., Zamore P.D., Aronin N. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 2009, 19:774-778.
31. Apffel A., Chakel J.A., Fischer S., Lichtenwalter K., Hancock W.S. Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry. Anal. Chem. 1997, 69:1320-1325.
32. Gilar M. Analysis and purification of synthetic oligonucleotides by reversed-phase high-performance liquid chromatography with photodiode array and mass spectrometry detection. Anal. Biochem. 2001, 298:196-206.
33. Zou Y., Tiller P., Chen I.W., Beverly M., Hochman J. Metabolite identification of small interfering RNA siRNA by high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:1871-1881.
34. Beverly M., Hartsough K., Machemer L. Liquid chromatography/electrospray mass spectrometric analysis of metabolites from an inhibitory RNA siRNA. Rapid Commun. Mass Spectrom. 2005, 19:1675-1682.
35. McCarthy S.M., Gilar M., Gebler J. Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA. Anal. Biochem. 2009, 390:181-188.
36. Zhong Z., Li Q., Zhang J.A. Analysis of cationic liposomes by reversed-phase HPLC with evaporative light-scattering detection. J. Pharm. Biomed. Anal. 2010, 51:947-951.
37. Ames B.N., Lee F.D., Durston W.E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. USA 1973, 70:782-786.
38. Huber C.G., Berti G.N. Detection of partial denaturation in AT-rich DNA fragments by ion-pair reversed-phase chromatography. Anal. Chem. 1996, 68:2959-2965.
39. Lei B., Li S., Xi L., Li J., Liu H., Yao X. Novel approaches for retention time prediction of oligonucleotides in ion-pair reversed-phase high-performance liquid chromatography. J. Chromatogr. A 2009, 1216:4434-4439.
40. Love K.T., Mahon K.P., Levins C.G., Whitehead K.A., Querbes W., Dorkin J.R., Qin J., Cantley W., Qin L.L., Racie T., Frank-Kamenetsky M., Yip K.N., Alvarez R., Sah D.W.Y., deFougerolles A., Fitzgerald K., Koteliansky V., Akinc A., Langer R., Anderson D.G. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA 2010, 107:1864-1869.
41. Dolan J.W. LC troubleshooting: variability-How to control it. LCGC North 2007, 25:360-366.
42. International Conference on Harmonization, Validation of Analytical Procedures: Test and Methodology (Q2R1), ICH, Food and Drug Administration, 1996 and 2005.
43. Center for Drug Evaluation and Research, Reviewer Guidance: Validation of Chromatographic Methods, CDER, 1994, pp. 1-30.